34 research outputs found
Cardioprotective effect of succinate dehydrogenase inhibition in rat hearts and human myocardium with and without diabetes mellitus
Abstract Ischemia reperfusion (IR) injury may be attenuated through succinate dehydrogenase (SDH) inhibition by dimethyl malonate (DiMAL). Whether SDH inhibition yields protection in diabetic individuals and translates into human cardiac tissue remain unknown. In isolated perfused hearts from 24 weeks old male Zucker diabetic fatty (ZDF) and age matched non-diabetic control rats and atrial trabeculae from patients with and without diabetes, we compared infarct size, contractile force recovery and mitochondrial function. The cardioprotective effect of a 10âminutes DiMAL administration prior to global ischemia and ischemic preconditioning (IPC) was evaluated. In non-diabetic hearts exposed to IR, DiMAL 0.1âmM reduced infarct size compared to IR (55âÂąâ7% vs. 69âÂąâ6%, pâ<â0.05). Mitochondrial respiration was reduced by DiMAL 0.6âmM compared to sham and DiMAL 0.1âmM (pâ<â0.05). In diabetic hearts an increased concentration of DiMAL (0.6âmM) was required for protection compared to IR (64âÂąâ13% vs. 79âÂąâ8%, pâ<â0.05). Mitochondrial function remained unchanged. In trabeculae from humans without diabetes, IPC and DiMAL improved contractile force recovery compared to IR (43âÂąâ12% and 43âÂąâ13% vs. 23âÂąâ13%, pâ<â0.05) but in patients with diabetes only IPC provided protection compared to IR (51âÂąâ15% vs. 21âÂąâ8%, pâ<â0.05). Neither IPC nor DiMAL modulated mitochondrial respiration in patients. Cardioprotection by SDH inhibition is possible in human tissue, but depends on diabetes status. The narrow therapeutic range and discrepancy in respiration between experimental and human studies may limit clinical translation
Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent
OBJECTIVES: To compare the efficacy and safety of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (O-SES) in patients with and without acute coronary syndrome (ACS) included in the SORT OUT X study.BACKGROUND: The incidence of target lesion failure (TLF) after treatment with modern drug-eluting stents has been reported to be significantly higher in patients with ACS when compared to patients without ACS. Whether the results from the SORT OUT X study apply to patients with and without ACS remains unknown.METHODS: In total, 3146 patients were randomized to stent implantation with DTS (nâ=â1578; ACS: nâ=â856) or O-SES (nâ=â1568; ACS: nâ=â854). The primary end point, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.RESULTS: At 1 year, the rate of TLF was higher in the DTS group compared to the O-SES group, both among patients with ACS (6.7% vs. 4.1%; incidence rate ratio: 1.65 [95% confidence interval, CI: 1.08-2.52]) and without ACS (6.0% vs. 3.2%; incidence rate ratio: 1.88 [95% CI: 1.13-3.14]). The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without ACS CONCLUSION: Compared to the O-SES, the DTS was associated with a higher risk of TLF at 12 months in patients with and without ACS. The differences were mainly explained by higher rates of TLR.</p
Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway
The citric acid cycle (CAC) metabolite fumarate has been proposed to be cardioprotective; however, its mechanisms of action remain to be determined. To augment cardiac fumarate levels and to assess fumarate's cardioprotective properties, we generated fumarate hydratase (Fh1) cardiac knockout (KO) mice. These fumarate-replete hearts were robustly protected from ischemia-reperfusion injury (I/R). To compensate for the loss of Fh1 activity, KO hearts maintain ATP levels in part by channeling amino acids into the CAC. In addition, by stabilizing the transcriptional regulator Nrf2, Fh1 KO hearts upregulate protective antioxidant response element genes. Supporting the importance of the latter mechanism, clinically relevant doses of dimethylfumarate upregulated Nrf2 and its target genes, hence protecting control hearts, but failed to similarly protect Nrf2-KO hearts in an in vivo model of myocardial infarction. We propose that clinically established fumarate derivatives activate the Nrf2 pathway and are readily testable cytoprotective agents. Š 2012 Elsevier Inc
Study design and experimental protocol.
<p>Overview of groups, number of animals (<b>N</b>) and experimental protocols. <b>KH-buffer:</b> Krebs-Henseleit buffer.</p
Cardioprotective effect of combination therapy by mild hypothermia and local or remote ischemic preconditioning in isolated rat hearts
10.1038/s41598-020-79449-xScientific Reports11126
Glucose metabolism prior to ischemia-reperfusion.
<p>Glucose uptake â glycolysis- and glucose oxidation rates during stabilization. Mean Âą SEM. Black bars: Control, White bars: ZDF.</p
Glucose metabolism during reperfusion.
<p><b>A</b>: Glycolysis and <b>B:</b> Glucose oxidation rates during reperfusion at 6, 12 and 24 weeks. Mean Âą SEM. Closed symbols: Control, Open symbols: ZDF. P-values indicate differences between control and ZDF from 0â5 and 10â30 minutes of reperfusion, respectively.</p